Seer (SEER) Proxy filing summary

Executive summary

• Annual Meeting scheduled for July 28, 2026, with a critical vote on board composition and company direction.

• Two activist shareholders have submitted director nominations and acquisition proposals below the company's cash value.

• Board urges support for its seven nominees, emphasizing a clear strategy to expand the proteomics market.

• Forward-looking statements highlight ongoing innovation, financial discipline, and growth plans.

Voting matters and shareholder proposals

• Shareholders are asked to vote for seven board nominees using the BLUE proxy card.

• Activist investors Radoff and Torok propose three unsolicited acquisition offers and alternate director nominees.

• Board opposes activist proposals, citing lack of relevant experience and risk to long-term value.

Board of directors and corporate governance

• Board described as independent, highly engaged, and experienced in life sciences and capital markets.

• Nominees include founders, major investors, and leaders with deep sector expertise.

• Board composition is positioned as critical to executing the company's long-term strategy.